The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 12, 2025

Filed:

Feb. 08, 2019
Applicant:

Dragonfly Therapeutics, Inc., Waltham, MA (US);

Inventors:

Gregory P. Chang, Medford, MA (US);

Ann F. Cheung, Lincoln, MA (US);

Asya Grinberg, Lexington, MA (US);

Eva Gutierrez, Waltham, MA (US);

William Haney, Wayland, MA (US);

Nicolai Wagtmann, Concord, MA (US);

Bradley M. Lunde, Lebanon, NH (US);

Bianka Prinz, Lebanon, NH (US);

Assignee:

Dragonfly Therapeutics, Inc., Waltham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 14/55 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2851 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4205 (2025.01); A61K 40/421 (2025.01); A61K 40/4215 (2025.01); A61K 40/4221 (2025.01); A61K 40/4224 (2025.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/283 (2013.01); C07K 16/2878 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2239/57 (2023.05); C07K 14/55 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01);
Abstract

Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.


Find Patent Forward Citations

Loading…